NASDAQ:CAPR - Capricor Therapeutics Stock Price, Price Target & More

$1.34 0.00 (0.00 %)
(As of 04/26/2018 03:23 AM ET)
Previous Close$1.34
Today's Range$1.33 - $1.4383
52-Week Range$0.63 - $4.25
Volume109,619 shs
Average Volume446,296 shs
Market Capitalization$37.69 million
P/E Ratio-3.05
Dividend YieldN/A
Beta-3.29

About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics logoCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio9.41%
Quick Ratio9.41%

Price-To-Earnings

Trailing P/E Ratio-3.05
Forward P/E Ratio-3.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.67 million
Price / Sales13.91
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book3.05

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins91.15%
Return on EquityN/A
Return on Assets-87.67%

Miscellaneous

Employees40
Outstanding Shares27,710,000

How to Become a New Pot Stock Millionaire

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $0.63 million. View Capricor Therapeutics' Earnings History.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Capricor Therapeutics.

What price target have analysts set for CAPR?

2 brokerages have issued 12-month target prices for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $9.00. On average, they expect Capricor Therapeutics' stock price to reach $5.5750 in the next year. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

Has Capricor Therapeutics been receiving favorable news coverage?

News articles about CAPR stock have been trending somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $1.34.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $37.69 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]


MarketBeat Community Rating for Capricor Therapeutics (CAPR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Capricor Therapeutics (NASDAQ:CAPR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Capricor Therapeutics in the last 12 months. Their average twelve-month price target is $5.5750, suggesting that the stock has a possible upside of 316.04%. The high price target for CAPR is $9.00 and the low price target for CAPR is $2.15. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.5750$5.3750$5.3750$4.3250
Price Target Upside: 316.04% upside218.05% upside218.05% upside336.87% upside

Capricor Therapeutics (NASDAQ:CAPR) Consensus Price Target History

Price Target History for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018HC WainwrightReiterated RatingBuy$9.00HighView Rating Details
7/22/2017Rodman & RenshawReiterated RatingBuy$2.15N/AView Rating Details
10/20/2016Roth CapitalSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Capricor Therapeutics (NASDAQ:CAPR) Earnings History and Estimates Chart

Earnings by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.42 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS

Capricor Therapeutics (NASDAQ CAPR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
3/14/2018Q4 2017($0.10)($0.11)$0.63 million$0.48 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.19)($0.12)$1.00 million$0.31 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.18)($0.16)$1.10 million$1.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)($0.17)$0.87 million$0.88 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.30)($0.14)$1.05 million$0.91 millionViewN/AView Earnings Details
11/10/2016Q316($0.27)($0.29)$1.12 million$0.75 millionViewN/AView Earnings Details
8/15/2016Q2($0.24)($0.26)$1.22 million$1.13 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 million$1.22 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 million$1.12 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 million$1.32 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 million$1.29 millionViewN/AView Earnings Details
5/12/2015Q1 2015($0.14)($0.23)$1.10 million$1.79 millionViewN/AView Earnings Details
3/18/2015Q4 2014($0.14)($0.16)$1.30 million$1.40 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.22)($0.13)$1.30 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)$1.04 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.10)$1.04 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.50)ViewN/AView Earnings Details
6/21/2013Q4 2012($11.50)ViewN/AView Earnings Details
8/14/2012Q2 2012($1.00)($0.40)ViewN/AView Earnings Details
5/15/2012Q1 2012($1.00)($0.95)ViewN/AView Earnings Details
11/14/2011Q3 2011($1.00)($1.45)ViewN/AView Earnings Details
8/15/2011Q2 2011($1.00)($1.25)ViewN/AView Earnings Details
5/16/2011Q1 2011($1.00)($1.70)ViewN/AView Earnings Details
3/14/2011Q4 2010($2.00)($1.15)ViewN/AView Earnings Details
11/12/2010Q3 2010($2.50)($2.60)ViewN/AView Earnings Details
8/16/2010Q2 2010($3.50)($2.30)ViewN/AView Earnings Details
5/14/2010Q1 2010($3.00)($3.50)ViewN/AView Earnings Details
3/3/2010Q4 2009($2.50)($2.90)ViewN/AView Earnings Details
11/12/2009Q3 2009($2.50)($4.00)ViewN/AView Earnings Details
8/13/2009Q2 2009($3.50)($5.20)ViewN/AView Earnings Details
5/14/2009Q1 2009($6.00)($3.70)ViewN/AView Earnings Details
3/9/2009Q4 2008($7.00)($6.15)ViewN/AView Earnings Details
11/13/2008Q3 2008($8.00)($6.90)ViewN/AView Earnings Details
8/14/2008Q2 2008($7.85)ViewN/AView Earnings Details
5/15/2008Q1 2008($6.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Capricor Therapeutics (NASDAQ:CAPR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 8.83%
Insider Trading History for Capricor Therapeutics (NASDAQ:CAPR)
Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ CAPR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2017Louis ManzoDirectorBuy10,000$3.10$31,000.00138,384View SEC Filing  
5/9/2017Sinai Medical Center CedarsMajor ShareholderBuy1,145,161$3.10$3,549,999.104,049,959View SEC Filing  
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.002,904,798View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.002,030View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.0011,156View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.002,100View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.402,592,298View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.005,950View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.003,173,354View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Capricor Therapeutics (NASDAQ CAPR) News Headlines

Source:
DateHeadline
Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular DystrophyWired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy
finance.yahoo.com - April 23 at 8:15 AM
Findings are the Basis for the HOPE-2 Clinical TrialFindings are the Basis for the HOPE-2 Clinical Trial
globenewswire.com - April 19 at 8:16 AM
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease ModelCapricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
finance.yahoo.com - April 19 at 8:16 AM
Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor DayCapricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
globenewswire.com - April 12 at 8:35 AM
Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor DayCapricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
finance.yahoo.com - April 12 at 8:35 AM
Capricor Therapeutics (CAPR) Upgraded by ValuEngine to "Sell"Capricor Therapeutics (CAPR) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 8 at 1:28 PM
Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018
finance.yahoo.com - April 6 at 5:41 PM
Capricor Therapeutics (CAPR) Stock Rating Upgraded by Zacks Investment ResearchCapricor Therapeutics (CAPR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:54 PM
Capricor Therapeutics (CAPR) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowCapricor Therapeutics (CAPR) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM
Capricor Therapeutics (CAPR) PT Set at $9.00 by HC WainwrightCapricor Therapeutics (CAPR) PT Set at $9.00 by HC Wainwright
www.americanbankingnews.com - March 29 at 11:16 AM
Capricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment ResearchCapricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:04 PM
Wired News – OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 DiabetesWired News – OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 Diabetes
finance.yahoo.com - March 27 at 8:27 AM
Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences - GlobeNewswire (press release)Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:48 AM
Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare ConferencesCapricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
finance.yahoo.com - March 21 at 8:48 AM
Capricor Therapeutics (CAPR) versus Versartis (VSAR) Critical ContrastCapricor Therapeutics (CAPR) versus Versartis (VSAR) Critical Contrast
www.americanbankingnews.com - March 16 at 5:22 AM
Capricor Therapeutics (CAPR) Posts  Earnings Results, Misses Estimates By $0.01 EPSCapricor Therapeutics (CAPR) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 15 at 10:45 AM
Capricor Therapeutics, Inc. to Host Earnings CallCapricor Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 14 at 7:07 PM
Has Capricor Therapeutics Inc (NASDAQ:CAPR) Improved Earnings Growth In Recent Times?Has Capricor Therapeutics Inc (NASDAQ:CAPR) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 14 at 7:07 PM
Earnings Preview For Capricor TherapeuticsEarnings Preview For Capricor Therapeutics
finance.yahoo.com - March 14 at 7:07 PM
Capricor posts 4Q profitCapricor posts 4Q profit
finance.yahoo.com - March 14 at 7:07 PM
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate UpdateCapricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
finance.yahoo.com - March 14 at 7:07 PM
Capricor Therapeutics (CAPR) Upgraded to "Buy" by Zacks Investment ResearchCapricor Therapeutics (CAPR) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 12 at 7:10 PM
Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on ... - GlobeNewswire (press release)Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:20 AM
Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
finance.yahoo.com - March 8 at 6:44 PM
Capricor Therapeutics (CAPR) Cut to "Hold" at Zacks Investment ResearchCapricor Therapeutics (CAPR) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 7 at 6:57 PM
Capricor Therapeutics (CAPR) Lifted to Buy at Zacks Investment ResearchCapricor Therapeutics (CAPR) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 6 at 7:00 PM
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on TuesdayCapricor Therapeutics (CAPR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
Brown Advisory Inc. Buys New Stake in Capricor Therapeutics Inc (CAPR)Brown Advisory Inc. Buys New Stake in Capricor Therapeutics Inc (CAPR)
www.americanbankingnews.com - March 2 at 5:10 AM
Capricor to Host Key Opinion Leader Lunch on March 9 - GlobeNewswire (press release)Capricor to Host Key Opinion Leader Lunch on March 9 - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM
Capricor to Host Key Opinion Leader Lunch on March 9Capricor to Host Key Opinion Leader Lunch on March 9
finance.yahoo.com - February 28 at 8:17 AM
Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - February 23 at 8:21 AM
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular DystrophyNew Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
finance.yahoo.com - February 22 at 5:38 PM
Capricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment ResearchCapricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 14 at 7:12 PM
Capricor Therapeutics (CAPR) Upgraded at Zacks Investment ResearchCapricor Therapeutics (CAPR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 13 at 7:00 PM
Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular DystrophyCapricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
finance.yahoo.com - February 12 at 9:44 AM
Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...)Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...)
www.streetinsider.com - February 5 at 3:40 PM
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy TherapyCapricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
finance.yahoo.com - February 5 at 3:40 PM
BRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT DesignationBRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation
www.reuters.com - February 5 at 9:34 AM
Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to HoldZacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold
www.americanbankingnews.com - February 2 at 6:42 PM
Who Are Capricor Therapeutics Inc’s (NASDAQ:CAPR) Major Shareholders?Who Are Capricor Therapeutics Inc’s (NASDAQ:CAPR) Major Shareholders?
finance.yahoo.com - January 30 at 3:43 PM
Capricor Therapeutics (CAPR) Receives Buy Rating from HC WainwrightCapricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - January 26 at 11:48 PM
 Capricor Therapeutics Inc (CAPR) Receives Consensus Rating of "Strong Buy" from Analysts Capricor Therapeutics Inc (CAPR) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 24 at 5:42 PM
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based TechnologiesCapricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
finance.yahoo.com - January 16 at 8:58 AM
 Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 30 at 7:46 AM
Capricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head ReviewCapricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head Review
www.americanbankingnews.com - December 29 at 9:30 AM
Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - December 18 at 8:58 AM
ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:23 PM
Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)
www.prnewswire.com - December 13 at 5:01 PM
BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome TechnologyBRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology
www.reuters.com - December 13 at 9:05 AM
Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome TechnologyCapricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
finance.yahoo.com - December 13 at 9:05 AM

SEC Filings

Capricor Therapeutics (NASDAQ:CAPR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.